Recent Advances in Inflammation & Allergy Drug Discovery

metrics 2024

Exploring breakthroughs in inflammation and allergy science.

Introduction

Recent Advances in Inflammation & Allergy Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed open-access journal dedicated to the dynamic fields of drug discovery, immunology, and allergy. Since its inception in 2021, this journal has emerged as a crucial platform for disseminating groundbreaking research and innovative methodologies that drive forward our understanding of inflammatory processes and allergic diseases. With an ISSN of 2772-2708 and an E-ISSN of 2772-2716, it is currently indexed in various categories, boasting a Q3 ranking in Drug Discovery and Immunology & Allergy, and a Q1 ranking in Medicine (miscellaneous) for 2022. Operating from the United Arab Emirates, the journal aims to bridge the gap between laboratory research and clinical application, offering a comprehensive collection of articles that are accessible to a broad audience. Through its commitment to open access, it ensures that critical findings are widely available, fostering collaboration and innovation among researchers, practitioners, and students alike. Join the scholarly community engaged in this vital area of research and contribute to the ongoing advancements in inflammation and allergy therapeutics.

Metrics 2024

SCIMAGO Journal Rank0.44
Journal Impact Factor1.20
Journal Impact Factor (5 years)1.20
H-Index37
Journal IF Without Self1.20
Eigen Factor0.00
Normal Eigen Factor0.01
Influence0.21
Immediacy Index0.10
Cited Half Life-
Citing Half Life7.50
JCI0.24
Total Documents348
WOS Total Citations30
SCIMAGO Total Citations1996
SCIMAGO SELF Citations43
Scopus Journal Rank0.44
Cites / Document (2 Years)0.86
Cites / Document (3 Years)2.00
Cites / Document (4 Years)4.15

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #115/272
Percentile 57.72
Quartile Q2
Drug Discovery in Pharmacology, Toxicology and Pharmaceutics
Rank #89/157
Percentile 43.31
Quartile Q3
Immunology and Allergy in Medicine
Rank #137/233
Percentile 41.20
Quartile Q3

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 290/354
Percentile 18.20
Quartile Q4

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 306/354
Percentile 13.56
Quartile Q4

Quartile History

Similar Journals

IN VIVO

Pioneering breakthroughs in anticancer research since 1987.
Publisher: INT INST ANTICANCER RESEARCHISSN: 0258-851XFrequency: 6 issues/year

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

MINI-REVIEWS IN MEDICINAL CHEMISTRY

Unveiling Breakthroughs in Therapeutics.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-5575Frequency: 20 issues/year

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

CURRENT PHARMACEUTICAL DESIGN

Innovating Drug Discovery, Shaping Tomorrow's Therapies
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Drug Research

Pioneering Insights for Future Therapies
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

MEDICINAL RESEARCH REVIEWS

Exploring Breakthroughs in Drug Discovery and Pharmacology
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

CURRENT OPINION IN PHARMACOLOGY

Shaping Tomorrow's Therapeutics Today
Publisher: ELSEVIER SCI LTDISSN: 1471-4892Frequency: 6 issues/year

Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

Translational Research

Advancing Health Through Innovative Research
Publisher: ELSEVIER SCIENCE INCISSN: 1931-5244Frequency: 12 issues/year

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

CURRENT MEDICINAL CHEMISTRY

Elevating Research Standards in Medicinal Chemistry.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 0929-8673Frequency: 42 issues/year

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

Annual Review of Pharmacology and Toxicology

Transforming research into impactful discoveries.
Publisher: ANNUAL REVIEWSISSN: 0362-1642Frequency: 1 issue/year

Annual Review of Pharmacology and Toxicology is a leading journal published by ANNUAL REVIEWS, renowned for its comprehensive and critical reviews of the fields of pharmacology and toxicology. With an esteemed history spanning from 1965 to the present and an impressive Q1 ranking in both categories, this journal stands at the forefront of scholarly communication in pharmacological sciences. Researchers are encouraged to submit cutting-edge studies that advance knowledge and innovation in drug development, safety assessments, and therapeutic practices. Although this journal does not currently offer Open Access options, it remains a vital resource for professionals and students who seek to stay updated with the latest high-impact research findings. The journal is indexed in Scopus, boasting remarkable rankings, including Rank #1 in Toxicology and Rank #4 in Pharmacology, reflecting its pivotal role in shaping the discourse in these dynamic fields.

ARCHIVES OF PHARMACAL RESEARCH

Exploring the frontiers of pharmacal science for a healthier future.
Publisher: PHARMACEUTICAL SOC KOREAISSN: 0253-6269Frequency: 12 issues/year

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.